These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
805 related articles for article (PubMed ID: 25104109)
1. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Fizazi K; Scher HI; Miller K; Basch E; Sternberg CN; Cella D; Forer D; Hirmand M; de Bono JS Lancet Oncol; 2014 Sep; 15(10):1147-56. PubMed ID: 25104109 [TBL] [Abstract][Full Text] [Related]
2. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Loriot Y; Miller K; Sternberg CN; Fizazi K; De Bono JS; Chowdhury S; Higano CS; Noonberg S; Holmstrom S; Mansbach H; Perabo FG; Phung D; Ivanescu C; Skaltsa K; Beer TM; Tombal B Lancet Oncol; 2015 May; 16(5):509-21. PubMed ID: 25888263 [TBL] [Abstract][Full Text] [Related]
3. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. Tombal B; Saad F; Penson D; Hussain M; Sternberg CN; Morlock R; Ramaswamy K; Ivanescu C; Attard G Lancet Oncol; 2019 Apr; 20(4):556-569. PubMed ID: 30770294 [TBL] [Abstract][Full Text] [Related]
4. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study. Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. Agarwal N; McQuarrie K; Bjartell A; Chowdhury S; Pereira de Santana Gomes AJ; Chung BH; Özgüroğlu M; Juárez Soto Á; Merseburger AS; Uemura H; Ye D; Given R; Cella D; Basch E; Miladinovic B; Dearden L; Deprince K; Naini V; Lopez-Gitlitz A; Chi KN; Lancet Oncol; 2019 Nov; 20(11):1518-1530. PubMed ID: 31578173 [TBL] [Abstract][Full Text] [Related]
6. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Chi KN; Protheroe A; Rodríguez-Antolín A; Facchini G; Suttman H; Matsubara N; Ye Z; Keam B; Damião R; Li T; McQuarrie K; Jia B; De Porre P; Martin J; Todd MB; Fizazi K Lancet Oncol; 2018 Feb; 19(2):194-206. PubMed ID: 29326030 [TBL] [Abstract][Full Text] [Related]
7. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Sternberg CN; de Bono JS; Chi KN; Fizazi K; Mulders P; Cerbone L; Hirmand M; Forer D; Scher HI Ann Oncol; 2014 Feb; 25(2):429-34. PubMed ID: 24478320 [TBL] [Abstract][Full Text] [Related]
8. Increased survival with enzalutamide in prostate cancer after chemotherapy. Scher HI; Fizazi K; Saad F; Taplin ME; Sternberg CN; Miller K; de Wit R; Mulders P; Chi KN; Shore ND; Armstrong AJ; Flaig TW; Fléchon A; Mainwaring P; Fleming M; Hainsworth JD; Hirmand M; Selby B; Seely L; de Bono JS; N Engl J Med; 2012 Sep; 367(13):1187-97. PubMed ID: 22894553 [TBL] [Abstract][Full Text] [Related]
9. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Beer TM; Hotte SJ; Saad F; Alekseev B; Matveev V; Fléchon A; Gravis G; Joly F; Chi KN; Malik Z; Blumenstein B; Stewart PS; Jacobs CA; Fizazi K Lancet Oncol; 2017 Nov; 18(11):1532-1542. PubMed ID: 29033099 [TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Basch E; Autio K; Ryan CJ; Mulders P; Shore N; Kheoh T; Fizazi K; Logothetis CJ; Rathkopf D; Smith MR; Mainwaring PN; Hao Y; Griffin T; Li S; Meyers ML; Molina A; Cleeland C Lancet Oncol; 2013 Nov; 14(12):1193-9. PubMed ID: 24075621 [TBL] [Abstract][Full Text] [Related]
11. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. Hussain M; Fizazi K; Saad F; Rathenborg P; Shore N; Ferreira U; Ivashchenko P; Demirhan E; Modelska K; Phung D; Krivoshik A; Sternberg CN N Engl J Med; 2018 Jun; 378(26):2465-2474. PubMed ID: 29949494 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Shore ND; Chowdhury S; Villers A; Klotz L; Siemens DR; Phung D; van Os S; Hasabou N; Wang F; Bhattacharya S; Heidenreich A Lancet Oncol; 2016 Feb; 17(2):153-163. PubMed ID: 26774508 [TBL] [Abstract][Full Text] [Related]
13. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Saad F; de Bono J; Shore N; Fizazi K; Loriot Y; Hirmand M; Franks B; Haas GP; Scher HI Eur Urol; 2015 Feb; 67(2):223-30. PubMed ID: 25171902 [TBL] [Abstract][Full Text] [Related]
14. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. Thiery-Vuillemin A; de Bono J; Hussain M; Roubaud G; Procopio G; Shore N; Fizazi K; Dos Anjos G; Gravis G; Joung JY; Matsubara N; Castellano D; Degboe A; Gresty C; Kang J; Allen A; Poehlein C; Saad F Lancet Oncol; 2022 Mar; 23(3):393-405. PubMed ID: 35157830 [TBL] [Abstract][Full Text] [Related]
15. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. Saad F; Thiery-Vuillemin A; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Kang J; Burgents J; Gresty C; Degboe A; Clarke NW Lancet Oncol; 2022 Oct; 23(10):1297-1307. PubMed ID: 36063830 [TBL] [Abstract][Full Text] [Related]
16. Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial. Heidenreich A; Chowdhury S; Klotz L; Siemens DR; Villers A; Ivanescu C; Holmstrom S; Baron B; Wang F; Lin P; Shore ND Eur Urol; 2017 Apr; 71(4):534-542. PubMed ID: 27497762 [TBL] [Abstract][Full Text] [Related]
17. Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide: Secondary Analysis of the PREVAIL and AFFIRM Randomized Clinical Trials. Armstrong AJ; Al-Adhami M; Lin P; Parli T; Sugg J; Steinberg J; Tombal B; Sternberg CN; de Bono J; Scher HI; Beer TM JAMA Oncol; 2020 Feb; 6(2):217-225. PubMed ID: 31830211 [TBL] [Abstract][Full Text] [Related]
18. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Cella D; Ivanescu C; Holmstrom S; Bui CN; Spalding J; Fizazi K Ann Oncol; 2015 Jan; 26(1):179-185. PubMed ID: 25361992 [TBL] [Abstract][Full Text] [Related]
19. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Clarke N; Wiechno P; Alekseev B; Sala N; Jones R; Kocak I; Chiuri VE; Jassem J; Fléchon A; Redfern C; Goessl C; Burgents J; Kozarski R; Hodgson D; Learoyd M; Saad F Lancet Oncol; 2018 Jul; 19(7):975-986. PubMed ID: 29880291 [TBL] [Abstract][Full Text] [Related]
20. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Evans CP; Higano CS; Keane T; Andriole G; Saad F; Iversen P; Miller K; Kim CS; Kimura G; Armstrong AJ; Sternberg CN; Loriot Y; de Bono J; Noonberg SB; Mansbach H; Bhattacharya S; Perabo F; Beer TM; Tombal B Eur Urol; 2016 Oct; 70(4):675-683. PubMed ID: 27006332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]